Differential cancer-specific survival with curative radiotherapy to the prostate for metastatic prostate cancer according to estimated survival by risk group

Int J Urol. 2023 Dec;30(12):1197-1199. doi: 10.1111/iju.15273. Epub 2023 Aug 10.

Authors

Masaki Shiota¹, Naoki Terada², Takahiro Kimura³, Hiroshi Kitamura⁴, Toshiyuki Kamoto², Masatoshi Eto¹; Japanese Urological Oncology Group (JUOG)

Affiliations

¹ Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
² Department of Urology, Miyazaki University, Miyazaki, Japan.
³ Department of Urology, Jikei University, Tokyo, Japan.
⁴ Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan.

PMID: 37565462
DOI: 10.1111/iju.15273

No abstract available

MeSH terms

Humans
Male
Prostate* / pathology
Prostate-Specific Antigen
Prostatic Neoplasms* / pathology

Substances

Prostate-Specific Antigen